WO2019180964A1 - Fgf21分泌促進用組成物 - Google Patents
Fgf21分泌促進用組成物 Download PDFInfo
- Publication number
- WO2019180964A1 WO2019180964A1 PCT/JP2018/011917 JP2018011917W WO2019180964A1 WO 2019180964 A1 WO2019180964 A1 WO 2019180964A1 JP 2018011917 W JP2018011917 W JP 2018011917W WO 2019180964 A1 WO2019180964 A1 WO 2019180964A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fgf21
- secretion
- composition
- bifidobacterium
- food
- Prior art date
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 title claims abstract description 131
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 title claims abstract description 131
- 239000000203 mixture Substances 0.000 title claims abstract description 128
- 230000028327 secretion Effects 0.000 title claims abstract description 105
- 230000001737 promoting effect Effects 0.000 title claims abstract description 82
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 50
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 235000013305 food Nutrition 0.000 claims description 94
- 241000894006 Bacteria Species 0.000 claims description 85
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 42
- 208000024891 symptom Diseases 0.000 claims description 41
- 238000004519 manufacturing process Methods 0.000 claims description 31
- 230000036760 body temperature Effects 0.000 claims description 28
- 241000186012 Bifidobacterium breve Species 0.000 claims description 27
- 210000004204 blood vessel Anatomy 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 208000035475 disorder Diseases 0.000 claims description 20
- 235000019629 palatability Nutrition 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 18
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 18
- 230000002631 hypothermal effect Effects 0.000 claims description 18
- 230000002265 prevention Effects 0.000 claims description 18
- 235000013406 prebiotics Nutrition 0.000 claims description 17
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 15
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 15
- 230000007505 plaque formation Effects 0.000 claims description 15
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 15
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 14
- 208000006029 Cardiomegaly Diseases 0.000 claims description 14
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 claims description 14
- 206010063837 Reperfusion injury Diseases 0.000 claims description 14
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 14
- 208000010125 myocardial infarction Diseases 0.000 claims description 14
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims description 13
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims description 13
- 230000002792 vascular Effects 0.000 claims description 13
- 206010063547 Diabetic macroangiopathy Diseases 0.000 claims description 12
- 206010016326 Feeling cold Diseases 0.000 claims description 12
- 206010021113 Hypothermia Diseases 0.000 claims description 12
- 229960000511 lactulose Drugs 0.000 claims description 12
- 230000007812 deficiency Effects 0.000 claims description 10
- 238000012423 maintenance Methods 0.000 claims description 10
- 230000004224 protection Effects 0.000 claims description 9
- 230000006872 improvement Effects 0.000 claims description 2
- 239000000047 product Substances 0.000 description 67
- 235000013361 beverage Nutrition 0.000 description 50
- 241000124008 Mammalia Species 0.000 description 32
- 239000000843 powder Substances 0.000 description 23
- 229920001542 oligosaccharide Polymers 0.000 description 20
- 150000002482 oligosaccharides Chemical class 0.000 description 17
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 16
- 235000009508 confectionery Nutrition 0.000 description 15
- 235000013336 milk Nutrition 0.000 description 13
- 239000008267 milk Substances 0.000 description 13
- 210000004080 milk Anatomy 0.000 description 13
- 101100120063 Homo sapiens FGF21 gene Proteins 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 235000000346 sugar Nutrition 0.000 description 10
- 241001608472 Bifidobacterium longum Species 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 229940009291 bifidobacterium longum Drugs 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- 235000015140 cultured milk Nutrition 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 235000013376 functional food Nutrition 0.000 description 8
- 239000004310 lactic acid Substances 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 108010046377 Whey Proteins Proteins 0.000 description 6
- 102000007544 Whey Proteins Human genes 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 235000019640 taste Nutrition 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 244000144972 livestock Species 0.000 description 5
- -1 patches Substances 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000004278 EU approved seasoning Substances 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- 229930091371 Fructose Natural products 0.000 description 4
- 239000005715 Fructose Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 235000011194 food seasoning agent Nutrition 0.000 description 4
- 229930182830 galactose Natural products 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 150000002772 monosaccharides Chemical class 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 239000005862 Whey Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical class [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 229940126864 fibroblast growth factor Drugs 0.000 description 3
- 235000013350 formula milk Nutrition 0.000 description 3
- 235000013611 frozen food Nutrition 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000019426 modified starch Nutrition 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 150000004043 trisaccharides Chemical class 0.000 description 3
- 235000021119 whey protein Nutrition 0.000 description 3
- 235000020138 yakult Nutrition 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- VOLMSPGWNYJHQQ-UHFFFAOYSA-N 3,5-dihydroxy-6-methyl-2,3-dihydropyran-4-one Chemical compound CC1=C(O)C(=O)C(O)CO1 VOLMSPGWNYJHQQ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 244000294411 Mirabilis expansa Species 0.000 description 2
- 235000015429 Mirabilis expansa Nutrition 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- FYGDTMLNYKFZSV-ANKSBSNASA-N alpha-D-Gal-(1->4)-beta-D-Gal-(1->4)-D-Glc Chemical group O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-ANKSBSNASA-N 0.000 description 2
- 239000008122 artificial sweetener Substances 0.000 description 2
- 235000021311 artificial sweeteners Nutrition 0.000 description 2
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 235000021056 liquid food Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000013536 miso Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 235000021110 pickles Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000008476 powdered milk Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 235000013580 sausages Nutrition 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000013322 soy milk Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- WVBINZLSBQRJFB-UHFFFAOYSA-N 2,3-dihydro-3,5-dihydroxy-6-methyl-4H-pyran-4-one Natural products CC1OC=C(O)C(=O)C1O WVBINZLSBQRJFB-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 description 1
- 102100024802 Fibroblast growth factor 23 Human genes 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 description 1
- 101001051973 Homo sapiens Fibroblast growth factor 23 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 241000533293 Sesbania emerus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 235000019647 acidic taste Nutrition 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229940118852 bifidobacterium animalis Drugs 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000012813 breadcrumbs Nutrition 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 235000020299 breve Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 235000014613 canned/preserved soup Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- OENDOEZBSDLANK-UHFFFAOYSA-N dimagnesiomagnesium Chemical compound [Mg][Mg][Mg] OENDOEZBSDLANK-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N hexanedioic acid Natural products OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 235000014109 instant soup Nutrition 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000016046 other dairy product Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000029964 regulation of glucose metabolic process Effects 0.000 description 1
- 230000028503 regulation of lipid metabolic process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000019600 saltiness Nutrition 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 239000004460 silage Substances 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 125000005624 silicic acid group Chemical class 0.000 description 1
- NGHMEZWZOZEZOH-UHFFFAOYSA-N silicic acid;hydrate Chemical compound O.O[Si](O)(O)O NGHMEZWZOZEZOH-UHFFFAOYSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 235000020206 standard milk formula Nutrition 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000019583 umami taste Nutrition 0.000 description 1
- 230000003845 vascular endothelial function Effects 0.000 description 1
- 230000009441 vascular protection Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Definitions
- the present invention relates to a composition for promoting secretion of fibroblast growth factor 21 (FGF21). Specifically, the present invention relates to a composition for promoting fibroblast growth factor 21 (FGF21) secretion, which comprises a Bifidobacterium bacterium as an active ingredient.
- FGF21 is a secretory polypeptide belonging to a subfamily of fibroblast growth factor (FGF) including FGF19, FGF21, and FGF23 (Non-patent Document 1).
- FGF21 is heparin-independent and functions as a hormone in the regulation of glucose metabolism, lipid metabolism, and energy metabolism. Increased secretion of FGF21 has been reported to increase lipid utilization at the whole body level, increase energy consumption, suppress triglyceride accumulation in the liver, induce fatty acid oxidation, and the like (Non-Patent Document 2). 3). Moreover, when a subject ingests sucrose, the FGF21 density
- FGF21 is reported to be important for maintaining body temperature in the neonatal period that is prone to hypothermia, as the body temperature rises due to an increase in serum FGF21 concentration and FGF21 gene expression in the liver.
- Non-Patent Document 5 FGF21 has been reported to be important for the protection of cardiac function in subjects with myocardial infarction, ischemia-reperfusion injury, cardiac hypertrophy, diabetic cardiomyopathy, and the like.
- FGF21 has been reported to protect blood vessels from plaque formation by improving vascular endothelial function in atherosclerosis (Non-patent Documents 7 and 8).
- An object of the present invention is to provide a novel composition that promotes secretion of FGF21.
- the present inventors have found that a Bifidobacterium genus bacterium exhibits an FGF21 secretion-promoting action in a mammal ingested (including a case of “administered”), and to complete the present invention. It came.
- the present invention is a composition for promoting FGF21 secretion, comprising Bifidobacterium as an active ingredient.
- the FGF21 secretion promoting composition is preferably used for controlling palatability, maintaining body temperature, or protecting blood vessels.
- the FGF21 secretion promoting composition is preferably used for the prevention or treatment of unbalanced diet, coldness, hypothermia, myocardial infarction, ischemia-reperfusion injury, cardiac hypertrophy, diabetic cardiomyopathy, arteriosclerosis or vascular plaque formation. It is an aspect.
- the FGF21 secretion promoting composition preferably includes prebiotics.
- the prebiotic is preferably lactulose, raffinose and galactooligosaccharide.
- the Bifidobacterium genus bacterium is Bifidobacterium breve.
- the Bifidobacterium breve is preferably Bifidobacterium breve M-16V (NITE BP-02622).
- the FGF21 secretion promoting composition is preferably a food or drink composition.
- the FGF21 secretion promoting composition is a pharmaceutical composition.
- Another aspect of the present invention is the use of a bacterium belonging to the genus Bifidobacterium in the manufacture of a composition for preventing or improving a disease, symptom, symptom, or disorder caused by FGF21 production failure and / or secretion failure. It is. Another aspect of the present invention is a bacterium belonging to the genus Bifidobacterium which is used for prevention or amelioration of a disease, symptom, symptom or disorder caused by FGF21 production failure and / or secretion failure.
- Another aspect of the present invention is the use of a bacterium belonging to the genus Bifidobacterium for the prevention or amelioration of a disease, symptom, symptom or disorder caused by FGF21 production failure and / or secretion failure.
- another aspect of the present invention includes the step of administering a Bifidobacterium bacterium to a subject in need of prevention or amelioration of a disease, symptom, symptom or disorder caused by FGF production deficiency and / or secretion deficiency.
- a method for preventing or ameliorating a disease, symptom, symptom or disorder caused by FGF21 production failure and / or secretion failure is preventing or ameliorating a disease, symptom, symptom or disorder caused by FGF21 production failure and / or secretion failure.
- a novel composition that promotes the secretion of FGF21 can be provided.
- the composition for promoting secretion of FGF21 of the present invention contains Bifidobacterium as an active ingredient.
- this bacterium may be referred to as “the present bacterium”.
- the composition for promoting FGF21 secretion of the present invention is a concept including a mixture, and it does not matter whether the components of the composition for promoting FGF21 secretion are uniform or non-uniform.
- This bacterium which is an active ingredient of the composition for promoting FGF21 secretion of the present invention, has an action of promoting FGF21 secretion.
- the FGF21 secretion-promoting action in the present invention means that when a mammal ingests the present bacterium (including the case of “administered” in the present specification), it is not ingested (in the present specification, the case of “not administered”). This means that the amount of FGF21 secreted is larger than that of the case.
- the large secretion amount of FGF21 may be attributed to the fact that the expression of FGF21 gene is turned on from off, may be attributed to the enhanced expression of FGF21 gene, or may be attributed to FGF21.
- the FGF21 gene is preferably a liver FGF21 gene. Moreover, it can be judged that the secretion amount of FGF21 is large by measuring the FGF21 density
- Mammals include humans, cows, sheep, goats, pigs, dogs, cats, horses and the like. Preferably it is a human. In the present specification, a mammal may be described as a “subject”.
- the Bifidobacterium in the present invention is a Gram-positive obligate anaerobe.
- Bifidobacterium is not particularly limited as long as it can promote secretion of FGF21 when the bacterium is ingested by a mammal.
- Bifidobacterium longum subsp. Longum, Bifidobacterium lactis, Bifidobacterium animalis, Bifidobacterium breve ( Bifidobcterium breve), Bifidobacterium longum subsp. Infantis, Bifidobacterium adolescentis, etc. can be used.
- Bifidobacterium longum, subspecies longum may be simply abbreviated as Bifidobacterium longum.
- Bifidobacterium longum subspecies infantis may be simply abbreviated as Bifidobacterium infantis.
- Bifidobacterium breve Bifidobacterium longum subspecies longum, and Bifidobacterium longum subspecies infantis are preferred.
- Bifidobacterium breve FERM BP-11175 Bifidobacterium breve M-16V (NITE BP-02622), Bifidobacterium longum subspecies longum BB536 (NITE BP-02621) And Bifidobacterium longum sub-species Infantis M-63 (NITE BP-02623) is more preferred.
- Bacteria to which the FERM BP-11175 accession number has been assigned were issued on August 25, 2009 at the National Institute of Advanced Industrial Science and Technology, Patent Biological Deposit Center (currently the National Institute for Product Evaluation Technology Patent Biological Deposit Center, 292-0818 2-5-8 Kazusa-Kamashita, Kisarazu City, Chiba Prefecture Room 120) has been deposited internationally based on the Budapest Treaty.
- the bacteria with the NITE BP-02622 accession number was issued on January 26, 2018, the National Institute for Product Evaluation and Technology Patent Microorganisms Deposit Center (2-5-Kazusa Kamashizu, Kisarazu City, Chiba Prefecture 292-0818). 8 Room No.
- NITE BP-02622 accession number was deposited with the NITE BP-02622 accession number under the Budapest Treaty.
- the bacteria with the NITE BP-02621 accession number was issued on January 26, 2018, and the National Institute for Product Evaluation Technology Patent Microorganisms Deposit Center (2-5-Kazusa Kamashizu, Kisarazu City, 292-0818, Japan) 8 Room 122) was deposited with NITE BP-02621 under an international deposit based on the Budapest Treaty.
- the bacteria with the NITE BP-02623 accession number was issued on January 26, 2018, and is based on the Patent Microorganism Depositary Center, Product Evaluation Technology Foundation (Kazusa Kamashi, Kisarazu City, 292-0818, Japan) 8 Room 122), which was deposited with NITE BP-02623 under an international deposit based on the Budapest Treaty.
- the Bifidobacterium genus bacterium of the present invention is not limited to the deposited bacterium, and may be a bacterium substantially equivalent to the deposited bacterium.
- the bacterium substantially equivalent to the deposited bacterium is a bacterium belonging to the same or the same kind as the deposited bacterium, and when the bacterium is ingested by a mammal, the mammal can promote the secretion of FGF21.
- the base sequence of the 16S rRNA gene has a homology of 98% or more, preferably 99% or more, more preferably 100% with the base sequence of the 16S rRNA gene of the deposited bacterium, and preferably in addition to the homology A bacterium having the same mycological properties as the deposited bacterium.
- the Bifidobacterium genus bacterium of the present invention is selected from the deposited bacterium or a bacterium substantially equivalent thereto, mutation treatment, genetic recombination, selection of a natural mutant, etc. Bacteria bred by may be used.
- the present bacterium may be a bacterial cell or a culture containing the cell. Further, the bacterium may be a live bacterium or a dead bacterium, and may be both a live bacterium and a dead bacterium, but is preferably a live bacterium.
- various additional operations such as freeze-drying can be performed after the culture as long as the effects of the present invention are not impaired. The additional operation is preferably one in which viability of viable bacteria is high.
- This bacterium can be easily obtained, for example, by culturing the bacterium.
- the method for culturing is not particularly limited as long as this bacterium can grow, and the method usually used for culturing Bifidobacterium (Bifidobacteria) can be appropriately modified as necessary.
- the culture temperature may be 25-50 ° C, preferably 35-40 ° C.
- the culture may be performed under anaerobic conditions or anaerobic conditions, but is preferably performed under anaerobic conditions.
- the culture can be performed while anaerobic gas such as carbon dioxide gas is aerated.
- the medium for culturing this bacterium is not particularly limited, and a medium usually used for culturing Bifidobacterium can be appropriately modified as necessary. That is, as the carbon source, for example, saccharides such as galactose, glucose, fructose, mannose, cellobiose, maltose, lactose, sucrose, trehalose, starch, starch hydrolyzate, and molasses can be used according to the utilization.
- the nitrogen source for example, ammonium salts such as ammonia, ammonium sulfate, ammonium chloride, and ammonium nitrate, and nitrates can be used.
- inorganic salts examples include sodium chloride, potassium chloride, potassium phosphate, magnesium sulfate, calcium chloride, calcium nitrate, manganese chloride, and ferrous sulfate.
- Organic components such as peptone, soybean powder, defatted soybean meal, meat extract, yeast extract and the like may also be used.
- an MRS medium can be preferably used as the prepared medium.
- the composition for promoting FGF21 secretion of the present invention preferably contains prebiotics.
- Prebiotics are indigestible food ingredients that have a beneficial effect on the host and improve the health of the host by selectively changing the growth and activity of certain bacteria in the large intestine.
- the prebiotic is not particularly limited as long as it can promote the secretion of FGF21 when ingested by a mammal together with the present bacterium.
- lactulose, raffinose, galactooligosaccharide, fructooligosaccharide, soybean oligosaccharide, milk fruit Oligosaccharides, xylo-oligosaccharides, isomali-oligosaccharides, coffee bean manno-oligosaccharides, gluconic acid, polydextrose, inulin and the like are preferred, and lactulose, raffinose and galactooligosaccharide are more preferred.
- Lactulose is a disaccharide composed of fructose and galactose (4-O- ⁇ -D-galactopyranosyl-D-fructose, Gal ⁇ 1-4 Fru), and is known in the art, for example, JP-A-3-169888. And by the method described in JP-A-6-228179.
- a commercial product for example, manufactured by Morinaga Milk Industry Co., Ltd.
- Raffinose is a trisaccharide ( ⁇ -D-fructofuranosyl- ⁇ -D-galactopyranosyl- (1-6) - ⁇ -D-glucopyranoside, Gal ⁇ 1 bound to fructose, galactose and glucose one by one. -6 Glc ⁇ 1-2 ⁇ Fru) and described in known methods such as “Food New Material Effective Utilization Technology Series No. 6,“ Raffinose ”, page 2, Confectionery Technology Center, 1996”. It can be manufactured by the method. For raffinose, a commercially available product (for example, manufactured by Nippon Sugar Sugar Co., Ltd.) can also be used.
- Galacto-oligosaccharide is an oligosaccharide having a structure represented by Gal- (Gal) n-Glc (n is 1 to 3, ⁇ -1,4 bond or ⁇ -1,6 bond) or a mixture thereof.
- Galactooligosaccharides are industrially produced by transfer reaction with ⁇ -galactosidase using lactose as a raw material, and the main component is 4′-galactosyl lactose (4′-GL), which is a trisaccharide in which one galactose is bonded to the non-reducing end of lactose. ).
- As the galactooligosaccharide a commercially available product (for example, manufactured by Yakult Pharmaceutical Co., Ltd.) can also be used.
- the galactooligosaccharide may be one kind or a mixture of two or more kinds.
- the FGF21 secretion promoting composition of the present invention enhances the function (activity) mediated by FGF21 in the mammal by promoting secretion of FGF21 in the mammal ingesting it. Therefore, the FGF21 secretion promoting composition of the present invention can be used to enhance the function (activity) mediated by FGF21. Examples of the function (activity) include preference adjustment, body temperature maintenance, blood vessel protection and the like. Therefore, the FGF21 secretion promoting composition of the present invention is preferably used for preference adjustment, body temperature maintenance, blood vessel protection and the like.
- the FGF21 secretion promoting composition of the present invention may be used for therapeutic use or non-therapeutic use. “Non-therapeutic” is a concept that does not include a medical act, that is, a treatment act on the human body by therapy.
- FGF21 is known to be involved in the preference adjustment of food and its taste (Patent Document 4).
- the intake of the composition for promoting secretion of FGF21 of the present invention is expected to adjust food palatability and taste palatability.
- the diet includes, for example, beverages such as food and alcohol.
- Taste includes sweetness, saltiness, acidity, bitterness, and umami.
- Preference adjustment includes preference enhancement and suppression.
- the enhancement of palatability means that when a mammal ingests this bacterium, the palatability of food, palatability of taste, etc. are enhanced than when the mammal does not ingest it.
- suppression of palatability means that when a mammal ingests this bacterium, the palatability of food, palatability of taste, and the like are suppressed more than when it is not ingested.
- the palatability for example, it is possible to reduce the bias in the types of diets that mammals ingest, so that a wide variety of diets can be ingested without dislikes, and the taste is adjusted.
- 1) liking and dislike due to diet bias is reduced, 2) palatability of sweet bias is suppressed, and 3) intake of sugar and artificial sweeteners is suppressed.
- Eating foods with a strong bitterness or sourness 5) Suppressing salty taste, prefers low-salt meals, 6) Suppresses alcohol preference .
- the food ingested by the mammal may be food or drink, but may also be a specific component. Therefore, the bias of the type of food consumed by mammals means that a large amount of specific food or drink or a specific component is consumed.
- the food and drink is not particularly limited.
- examples of the specific component include a sweetening component.
- the sweet component includes a saccharide sweet component and a non-sugar sweet component.
- sugar-based sweetening ingredient examples include sugars and sugar alcohols.
- the saccharides may be monosaccharides, disaccharides, trisaccharides or more, such as glucose, maltose, fructose, trehalose, lactose, fructooligosaccharides, galactooligosaccharides, xylo-oligosaccharides, whey oligosaccharides (registered trademark), soybeans.
- Examples thereof include oligosaccharides and isomaltoligosaccharides, and syrups and isomerized sugars, which are a mixture of monosaccharides, may also be used.
- sugar alcohol examples include sorbitol, mannitol, maltitol, xylitol, erythritol, reduced palatinose, and the like, and a reduced starch syrup obtained by reducing starch syrup, which is a mixture of monosaccharides.
- the non-carbohydrate sweet component includes a non-carbohydrate natural sweet component and a non-carbohydrate artificial sweetener.
- non-carbohydrate natural sweetening ingredients include stevia and glycyrrhizin.
- non-sugar artificial sweetening ingredients include saccharin, aspartame, acesulfame K, sucralose, and the like.
- body temperature maintenance refers to body temperature maintenance that prevents a state toward a hypothermia state by increasing body temperature. Maintaining body temperature, which prevents a state toward a hypothermia state by increasing body temperature, specifically means that if a mammal does not ingest this bacterium, ingestion of this bacterium in a state toward a hypothermia state reduces body temperature. It means preventing and preventing hypothermia.
- the hypothermia state is a state where the body temperature of the armpit is preferably 36.5 ° C. or less, more preferably 36.0 ° C. or less, further preferably 35.5 ° C. or less, and even more preferably 35.0 ° C. or less, or The deep body temperature shall be 35.0 ° C. or lower.
- the age of the mammal when the composition for promoting secretion of FGF21 of the present invention is used for maintaining body temperature is not particularly limited, but is preferably an infant.
- infant refers to those from the age of 1 to about 1 year old when the mammal is a human.
- a human infant corresponds to about 4 weeks of age (the last day of the 4th week) from the time of birth in mice.
- Blood vessel protection includes, for example, suppression of plaque formation in blood vessels.
- the plaque include plaque in arteriosclerosis.
- arteriosclerosis include atherosclerosis.
- blood vessels include cardiovascular blood vessels.
- composition for promoting FGF21 secretion of the present invention can be used for prevention or treatment of diseases, symptoms, symptoms or disorders that can be prevented or treated by promoting secretion of FGF21 in mammals. “Treatment” also includes improvement. Further, as described above, the FGF21 secretion promoting action in the present invention may be caused by the fact that the expression of the FGF21 gene has been turned on from off, or may be caused by the promotion of the expression of the FGF21 gene. In addition, since the FGF21 gene was originally expressed but not secreted, it may be caused by a state where it is secreted. Therefore, diseases and symptoms that can be prevented or treated by promoting the secretion of FGF21.
- the symptoms or disorders include diseases, symptoms, symptoms or disorders caused by FGF21 production deficiency and / or FGF21 secretion deficiency. Secretory failure also includes decreased secretion. Examples of such diseases, symptoms, symptoms, or disorders include unbalanced diet, coldness, hypothermia, myocardial infarction, ischemia-reperfusion injury, cardiac hypertrophy, diabetic cardiomyopathy, arteriosclerosis, vascular plaque formation, and the like. .
- the FGF21 secretion promoting composition of the present invention can be used as a food / beverage product composition, a pharmaceutical composition, or a feed composition.
- a food and drink composition for promoting FGF21 secretion, a pharmaceutical composition for promoting FGF21 secretion, and a feed composition for promoting FGF21 secretion can be provided.
- the food / beverage product composition for promoting FGF21 secretion of the present invention is not particularly limited as long as it contains this bacterium.
- the food / beverage composition may be in the form of a liquid, paste, gel-like solid, powder, etc., and may be a food / beverage, in addition to tablet confectionery, liquid food, etc., for example, bread, macaroni, spaghetti, noodles Flour products such as cake mix, fried flour, bread crumbs, instant noodles, cup noodles, retort / cooked food, cooked canned food, microwave food, instant soup / stew, instant miso soup / soup, canned soup, freeze-dried food, etc.
- Instant foods such as instant foods; canned agricultural products, canned fruits, jams, marmalades, pickles, boiled beans, dried agricultural products, processed cereals, etc .; canned fish products, fish ham / sausage, marine products Processed marine products such as kneaded products, marine delicacies, and tsukudani; livestock canned and pasted products, livestock processed products such as livestock ham and sausage; processed milk and milk drinks Milk and dairy products such as yogurt, lactic acid bacteria beverages, cheese, ice cream, prepared powdered milk, cream and other dairy products; fats and oils such as butter, margarine, vegetable oil; soy sauce, miso, sauces, tomato processing Basic seasonings such as seasonings, mirins, vinegars; mixed seasonings and foods such as cooking mixes, curry ingredients, sauces, dressings, noodle soups, spices, and other complex seasonings; frozen materials Frozen foods such as food, semi-cooked frozen food, cooked frozen food, etc .; caramel, candy, gummi, chewing gum,
- a supplement may be sufficient as food-drinks composition, for example, a tablet-like supplement may be sufficient as it.
- the bacterium can be ingested without being influenced by other foods with respect to the daily meal amount and calorie intake.
- the food / beverage composition for promoting secretion of FGF21 of the present invention can be produced by adding this bacterium to the raw material of a normal food / beverage product, and is the same as a normal food / beverage product except for adding this bacterium.
- the food-drinks composition may be manufactured through the fermentation process by this added bacteria. Examples of such a food and drink composition include lactic acid bacteria beverages and fermented milk.
- a raw material of a food / beverage product composition the raw material used for normal food / beverage products can be used.
- the manufactured food or drink composition can be taken orally.
- the food / beverage product composition for promoting secretion of FGF21 of the present invention includes a raw material for producing a food / beverage product composition, a food additive, and the like, which are added to the food / beverage product composition after the production process or production of the food / beverage product composition. included.
- this bacterium can be used as a starter for producing fermented milk.
- this bacterium can also be added later to the manufactured fermented milk.
- the content of the bacteria in FGF21 secretagogue food or drink composition of the present invention is appropriately set according to the embodiment of the food or beverage composition, in food or beverage composition in a total amount, typically, 1 ⁇ 10 4 ⁇ 1 It is preferably in the range of x10 13 cfu / g or 1 ⁇ 10 4 to 1 ⁇ 10 13 cfu / ml, 1 ⁇ 10 5 to 1 ⁇ 10 12 cfu / g or 1 ⁇ 10 5 to 1 ⁇ 10 12 More preferably, it is within the range of cfu / ml, and even more preferably within the range of 1 ⁇ 10 6 to 1 ⁇ 10 11 cfu / g or 1 ⁇ 10 6 to 1 ⁇ 10 11 cfu / ml.
- “Cfu” represents a colony forming unit. When the bacterium is dead, cfu / g or cfu / ml can be replaced with individual cells / g or individual cells
- the total amount of the bacteria is 1 ⁇ 10 6 to 1 ⁇ 10 12 cfu, preferably 1 g of the total amount of prebiotics. Is preferably 1 ⁇ 10 7 to 1 ⁇ 10 12 cfu, more preferably 1 ⁇ 10 8 to 1 ⁇ 10 12 cfu.
- the prebiotics are lactulose, raffinose, and galactooligosaccharide
- the weight ratio thereof is 1 to 9: 1 to 9: 1 to 9, preferably 2 to 8: 2 to 8: 2 to 8, It is preferably 3 to 7: 3 to 7: 3 to 7.
- the food / beverage product composition for promoting secretion of FGF21 of the present invention may be taken alone, or may be taken together with other food / beverage product compositions or food / beverage products or pharmaceutical compositions or medicines.
- other FGF21 secretion promoting food / beverage composition or food / beverage or pharmaceutical composition / medicine may be taken alone, or may be taken together with other food / beverage product compositions or food / beverage products or pharmaceutical compositions or medicines.
- other FGF21 secretion promoting food / beverage composition or food / beverage or pharmaceutical composition / medicine for controlling preference, maintaining body temperature, or protecting blood vessels by promoting secretion of FGF21 in mammals Or a pharmaceutical composition or medicine; taken together with a food or drink composition or food or drink or a pharmaceutical composition or medicine for the prevention or treatment of a disease, symptom, symptom or disorder that can be prevented or treated by promoting secretion of FGF21 Also good.
- the food / beverage product composition for promoting FGF21 secretion of the present invention can be sold as a food / beverage product composition or food / beverage product for which the use for promoting FGF21 secretion is displayed.
- the food / beverage product composition for promoting FGF21 secretion of the present invention is a food / beverage product composition or food / beverage product displaying uses for controlling palatability by maintaining secretion of FGF21, maintaining body temperature, or protecting blood vessels in mammals.
- the FGF21 secretion promoting food or drink composition of the present invention is a food or drink composition displaying a use for prevention or treatment of a disease, symptom, symptom, disorder or the like that can be prevented or treated by promoting FGF21 secretion. It can be sold as a food or drink.
- any other words can be used as long as the wording expresses an effect that is secondarily produced by promoting secretion of FGF21.
- the food / beverage product composition for promoting secretion of FGF21 of the present invention can be provided / sold as a food / beverage product composition or food / beverage product displaying uses such as probiotics (including health uses).
- food and beverage composition or food and beverage ingestion target "person who wants to live with Bifidobacteria”, "person who wants to improve intestinal environment”, “person who wants to adjust stomach condition”, “good intestine Provided / sold as "People who want to create an environment", “People who want to warm their bodies”, “People who want to correct and dislike", “People who want to improve blood vessel function", “People who want to improve blood flow”, etc. Is possible.
- the “display” means all acts for informing the consumer of the use, and if it is a display that can recall and analogize the use, the purpose of the display, the content of the display, the display Regardless of the object and medium to be processed, all fall under the “display” of the present invention. However, it is preferable to display in such an expression that the consumer can directly recognize the application.
- an act of describing the above-mentioned use in a product or a product packaging related to the FGF21 secretion-promoting food or drink composition or FGF21 secretion-promoting food or beverage of the present invention, or a product or product packaging in which the use is described To display, distribute or display the above use in the act of importing, displaying for import, transfer or delivery, importing, advertising regarding products, price list or transaction documents
- the act etc. which describe the said use and provide by an electromagnetic (Internet etc.) method etc. can be illustrated, and the display to advertising materials in sales sites, such as a packaging, a container, a catalog, a pamphlet, and a POP, and other documents are preferable.
- the display is preferably a display permitted by the government or the like (for example, a display that is approved based on various systems determined by the government and is performed in a mode based on such approval).
- health functional foods and the like more specifically health functional foods, health foods, functional foods, enteral nutrition foods, special purpose foods, nutritional functional foods, quasi drugs, etc.
- Other indications approved by the Consumer Affairs Agency for example, foods for specified health use, nutritional functional foods, functional indication foods, and indications approved under a similar system can be exemplified. Examples of the latter include labeling as food for specified health use, labeling as conditionally specified food for specified health use, labeling that affects the structure and function of the body, labeling for reducing disease risk, and functionality based on scientific evidence The display etc.
- the pharmaceutical composition for promoting FGF21 secretion of the present invention is not particularly limited as long as it contains this bacterium.
- the present bacterium may be used as it is, or may be formulated and used by mixing a physiologically acceptable liquid or solid pharmaceutical carrier.
- the dosage form of the pharmaceutical composition for promoting secretion of FGF21 of the present invention is not particularly limited, and specifically, tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules, syrups, suppositories. , Injections, ointments, patches, eye drops, nasal drops and the like.
- addition of excipients, binders, disintegrants, lubricants, stabilizers, flavoring agents, diluents, surfactants, or solvents for injections that are commonly used as pharmaceutical carriers Agents can be used.
- preparation carrier various organic or inorganic carriers can be used depending on the dosage form.
- examples of the carrier in the case of a solid preparation include excipients, binders, disintegrants, lubricants, stabilizers, and flavoring agents.
- excipient examples include sugar derivatives such as lactose, sucrose, glucose, mannitol and sorbit; starch derivatives such as corn starch, potato starch, ⁇ -starch, dextrin and carboxymethyl starch; crystalline cellulose, hydroxypropyl cellulose, Cellulose derivatives such as hydroxypropylmethylcellulose, carboxymethylcellulose, carboxymethylcellulose calcium; gum arabic; dextran; pullulan; silicate derivatives such as light anhydrous silicic acid, synthetic aluminum silicate, magnesium magnesium magnesium silicate; phosphate derivatives such as calcium phosphate; And carbonate derivatives such as calcium; sulfate derivatives such as calcium sulfate and the like.
- sugar derivatives such as lactose, sucrose, glucose, mannitol and sorbit
- starch derivatives such as corn starch, potato starch, ⁇ -starch, dextrin and carboxymethyl starch
- crystalline cellulose hydroxypropyl cellulose
- binder examples include gelatin, polyvinyl pyrrolidone, macrogol and the like in addition to the above excipients.
- disintegrant examples include, in addition to the above excipients, chemically modified starch or cellulose derivatives such as croscarmellose sodium, sodium carboxymethyl starch, and crosslinked polyvinylpyrrolidone.
- talc stearic acid
- stearic acid metal salts such as calcium stearate and magnesium stearate
- colloidal silica waxes such as pea gum and geirow
- boric acid glycol
- carboxylic acids such as fumaric acid and adipic acid
- Carboxylic acid sodium salts such as sodium benzoate
- sulfates such as sodium sulfate; leucine
- lauryl sulfates such as sodium lauryl sulfate and magnesium lauryl sulfate
- silicic acids such as anhydrous silicic acid and silicic acid hydrate; starch derivatives and the like It is done.
- the stabilizer examples include paraoxybenzoic acid esters such as methylparaben and propylparaben; alcohols such as chlorobutanol, benzyl alcohol and phenylethyl alcohol; benzalkonium chloride; acetic anhydride; sorbic acid and the like.
- flavoring agent examples include sweeteners, acidulants, and fragrances.
- a carrier used in the case of a liquid for oral administration a solvent such as water, a flavoring agent and the like can be mentioned.
- the content of the bacterium in the pharmaceutical composition for promoting secretion of FGF21 of the present invention is appropriately set depending on the dosage form, usage, age of the subject, sex, type of disease or symptom, symptom or disorder, its degree, and other conditions.
- the normal range and the preferred range are the same as those of the food / beverage product composition for promoting FGF21 secretion of the present invention.
- the pharmaceutical composition for promoting FGF21 secretion of the present invention contains prebiotics
- the total amount of the bacterium with respect to 1 g of the total amount of prebiotics is also the case of the food / beverage composition for promoting FGF21 secretion of the present invention. It is the same.
- the prebiotic is lactulose, raffinose, and galactooligosaccharide
- the weight ratio thereof is also the same as in the case of the food / beverage composition for promoting FGF21 secretion of the present invention.
- the administration time of the pharmaceutical composition for promoting secretion of FGF21 of the present invention is not particularly limited, and it is possible to select an appropriate administration time according to a method for preventing or treating a target disease, symptom, symptom or disorder. It may be administered prophylactically or used for maintenance therapy.
- the dosage form is preferably determined according to the dosage form, the patient's age, sex, other conditions, the degree of symptoms of the patient, and the like.
- the pharmaceutical composition for promoting FGF21 secretion of the present invention can be administered once or a plurality of times a day, or can be administered once every several days or weeks.
- the pharmaceutical composition for promoting secretion of FGF21 of the present invention may be administered alone, or may be administered together with other pharmaceutical compositions or medicines, food / beverage composition or food / beverage products.
- other FGF21 secretion-promoting pharmaceutical composition or pharmaceutical or food / beverage composition or food / beverage product pharmaceutical composition or pharmaceutical or food / beverage product for regulating preference, maintaining body temperature or protecting blood vessels by promoting secretion of FGF21 in mammals Composition or food or drink; may be taken together with a pharmaceutical composition or medicine or food or drink composition or food or drink for prevention or treatment of a disease, symptom, symptom or disorder that can be prevented or treated by promoting secretion of FGF21 Good.
- Examples of the feed composition for promoting secretion of FGF21 of the present invention include pet food, livestock feed, and fish feed.
- the FGF21 secretion promoting feed composition of the present invention is a general feed or a raw material thereof, such as cereals, potatoes, cocoons, fish meal, bone meal, fats and oils, skimmed milk powder, whey, mineral feed, yeasts, etc. It can be produced by mixing this bacterium with Moreover, a feed composition may be manufactured through the fermentation process by this added bacteria, for example like silage.
- the produced feed composition can be orally administered to general mammals, livestock, fish farms, pets and the like.
- the content of the bacterium in the feed composition for promoting FGF21 secretion of the present invention is appropriately set depending on the mode of the feed composition and the administration target, but the normal range and preferred range are the above-mentioned food and drink for promoting FGF21 secretion of the present invention.
- the total amount of this bacterium with respect to 1 g of the total amount of prebiotics is also the case of the food / beverage product composition for promoting FGF21 secretion of the present invention. It is the same.
- the prebiotic is lactulose, raffinose, and galactooligosaccharide
- the weight ratio thereof is also the same as in the case of the food / beverage composition for promoting FGF21 secretion of the present invention.
- Another aspect of the present invention is the use of Bifidobacterium in the manufacture of a composition for promoting FGF21 secretion.
- Another embodiment of the present invention is a Bifidobacterium genus bacterium used for promoting FGF21 secretion.
- Another aspect of the present invention is the use of Bifidobacterium to promote FGF21 secretion.
- Another aspect of the present invention is a method for promoting FGF21 secretion comprising the step of administering a Bifidobacterium bacterium to a mammal or the step of administering the FGF21 secretion promoting composition of the present invention to a mammal. is there.
- Another aspect of the present invention is to prevent or prevent FGF21 secretion by including the step of administering a Bifidobacterium bacterium to a mammal or the step of administering the FGF21 secretion promoting composition of the present invention to a mammal. It is a method for preventing or treating a disease, symptom, symptom, disorder or the like that can be treated.
- Another aspect of the present invention is the use of Bifidobacterium in the manufacture of a pharmaceutical composition, a food / beverage product composition, or a feed composition for controlling palatability, maintaining body temperature, or protecting blood vessels.
- Another aspect of the present invention is a bacterium belonging to the genus Bifidobacterium used for preference control, body temperature maintenance or blood vessel protection.
- Another aspect of the present invention is the use of Bifidobacterium for palatability control, body temperature maintenance or vascular protection.
- another aspect of the present invention provides a preference for promoting secretion of FGF21, comprising the step of administering a Bifidobacterium bacterium to a mammal or the step of administering the composition for promoting FGF21 secretion of the present invention to a mammal.
- a medicament for preventing or treating uneven eating, coldness, hypothermia, myocardial infarction, ischemia-reperfusion injury, cardiac hypertrophy, diabetic cardiomyopathy, arteriosclerosis or vascular plaque formation Use of Bifidobacterium in the manufacture of a composition, a food or drink composition, or a feed composition.
- another aspect of the present invention is a method for preventing or treating uneven eating, coldness, hypothermia, myocardial infarction, ischemia-reperfusion injury, cardiac hypertrophy, diabetic cardiomyopathy, arteriosclerosis or vascular plaque formation. It is a genus Fidobacterium.
- another aspect of the present invention is a method for preventing or treating uneven eating, coldness, hypothermia, myocardial infarction, ischemia-reperfusion injury, cardiac hypertrophy, diabetic cardiomyopathy, arteriosclerosis or vascular plaque formation.
- Use of bacteria belonging to the genus Fidobacterium includes a step of administering a Bifidobacterium genus bacterium to a mammal or a step of administering the FGF21 secretion promoting composition of the present invention to a mammal.
- a method for preventing or treating myocardial infarction, ischemia-reperfusion injury, cardiac hypertrophy, diabetic cardiomyopathy, arteriosclerosis or vascular plaque formation is a method for preventing or treating uneven eating, coldness, hypothermia, myocardial infarction, ischemia-reperfusion injury, cardiac hypertrophy, diabetic cardiomyopathy, arteriosclerosis or vascular plaque formation.
- Example 1 Effect of Bifidobacterium breve M-16V (NITE BP-02622) and lactulose, raffinose, and galactooligosaccharide on expression level of FGF21 gene in liver and FGF21 concentration in serum Doubled in starch Bifidobacterium breve M-16V (NITE BP-02622) cell powder (2.4 ⁇ 10 11 cfu / g) is suspended in physiological saline to prepare a 2.5 ⁇ 10 9 cfu / ml bifidobacteria solution did.
- Lactulose manufactured by Morinaga Milk Industry Co., Ltd.
- raffinose product name: Nitten Raffinose, manufactured by Nippon Sesame Sugar Co., Ltd.
- galactooligosaccharide are mixed and dissolved in distilled water at a weight ratio of 1: 1: 1, for a total final concentration of 250 mg / ml.
- An oligosaccharide stock solution was prepared.
- Galactooligosaccharide is a product obtained by removing monosaccharide and disaccharide from a commercial product (product name Oligomate 55N, manufactured by Yakult Pharmaceutical Co., Ltd.), Gal ⁇ 1-4Gal ⁇ 1-4Glc (4′-galactosyl lactose) is about 65% by weight, About 15% by weight of Gal ⁇ 1-6Gal ⁇ 1-4Glc (6′-galactosyl lactose) is contained.
- Saline a dilute solution obtained by diluting the above bifidobacteria solution 5 times with physiological saline (final concentration 5 ⁇ 10 8 cfu / ml bifidobacteria), saline and oligosaccharide stock solution were mixed at a volume ratio of 1: 4.
- (Final concentration 200 mg / ml oligosaccharide) and bifidobacteria solution and oligosaccharide stock solution mixed at a volume ratio of 1: 4 (final concentration 5 ⁇ 10 8 cfu / ml bifidobacteria, 200 mg / ml oligosaccharide) was a dose.
- Group B contains 5 ⁇ 10 7 cfu Bifidobacterium breve M-16V (NITE BP-02622)
- Group C contains 20 mg oligosaccharide
- Group D contains 20 mg oligosaccharide.
- 5 ⁇ 10 7 cfu Bifidobacterium breve M-16V NITE BP-02622.
- the serum FGF21 concentration was measured using an ELISA kit (R & D Systems).
- the expression level of FGF21 gene in the liver was measured by RT-PCR.
- a primer set in RT-PCR a primer of SEQ ID NO: 1 (CCTCTAGGTTTCTTTGCCAACAG) and a primer of SEQ ID NO: 2 (AAGCTGCAGGCCTCAGGAT) were used. The results are shown in Tables 1 and 2.
- the expression level of FGF21 in the liver was significantly higher in group B and group D than group A and group C at 21 days after birth.
- the FGF21 concentration in the serum was significantly higher in the group D than in the groups A, B, and C.
- Bifidobacterium breve M-16V (NITE BP-02622) is added to 3 mL of MRS liquid medium, anaerobically cultured at 37 ° C for 16 hours, the culture is concentrated, freeze-dried, and freeze-dried of bacteria A powder (bacterial powder) is obtained.
- the composition is obtained by uniformly mixing the bacterial powder and Whey protein concentrate (WPC). 20 g of the composition is dissolved in 200 g of water to obtain a composition for promoting FGF21 secretion.
- Administration of this composition can be expected to adjust palatability, maintain body temperature, and protect blood vessels. Furthermore, it can be used for prevention or treatment of uneven eating, coldness, hypothermia, myocardial infarction, ischemia-reperfusion injury, cardiac hypertrophy, diabetic cardiomyopathy, arteriosclerosis, and vascular plaque formation.
- Bifidobacterium breve M-16V (NITE BP-02622) is added to 3 mL of MRS liquid medium, anaerobically cultured at 37 ° C for 16 hours, the culture is concentrated, freeze-dried, and freeze-dried of bacteria A powder (bacterial powder) is obtained.
- Bifidobacterium breve M-16V (NITE BP-02622) is added to 3 mL of MRS liquid medium, anaerobically cultured at 37 ° C for 16 hours, the culture is concentrated, freeze-dried, and freeze-dried of bacteria A powder (bacterial powder) is obtained. Next, crystalline cellulose is put into a stirring granulator and mixed. Thereafter, purified water is added to granulate, and the granulated product is dried to obtain a granulated product containing bacterial extract components and excipients. Administration of this composition can be expected to adjust palatability, maintain body temperature, and protect blood vessels. Furthermore, it can be used for prevention or treatment of uneven eating, coldness, hypothermia, myocardial infarction, ischemia-reperfusion injury, cardiac hypertrophy, diabetic cardiomyopathy, arteriosclerosis, and vascular plaque formation.
- Bifidobacterium breve M-16V (NITE BP-02622) was added to 3 mL of MRS liquid medium, anaerobically cultured at 37 ° C for 16 hours, the culture was concentrated, freeze-dried, and the bacteria were freeze-dried A powder (bacterial powder) is obtained.
- the composition is obtained by uniformly mixing the bacterial powder and prebiotics (lacturose, raffinose and galactooligosaccharide). The composition is provided to the elderly as a liquid food for the elderly.
- Bifidobacterium breve M-16V (NITE BP-02622) intake is 1 ⁇ 10 8 to 1 ⁇ 10 10 CFU / kg body weight / day, and is served daily for breakfast for one week.
- CFU / kg body weight / day can be replaced with individual cells / kg body weight / day.
- Oral administration of the composition can be expected to adjust palatability, maintain body temperature, and protect blood vessels. Furthermore, it can be used for prevention or treatment of uneven eating, coldness, hypothermia, myocardial infarction, ischemia-reperfusion injury, cardiac hypertrophy, diabetic cardiomyopathy, arteriosclerosis, and vascular plaque formation.
- FIG. 5 A method for producing fermented milk to which Bifidobacterium breve M-16V (NITE BP-02622) is added is shown below.
- milk raw materials, water as required, other components, etc. are mixed, preferably homogenized, and heat sterilized. Homogenization treatment and heat sterilization treatment can be performed by conventional methods.
- a lactic acid bacteria starter is added (inoculated) to the heat-sterilized sterilized milky lotion and fermented while being kept at a predetermined fermentation temperature to obtain a fermented product.
- a card is formed by fermentation.
- lactic acid bacteria starter for example, lactic acid bacteria usually used for the production of yogurt such as Lactobacillus bulgaricus, Lactococcus lactis and Streptococcus thermophilus can be used.
- the pH reaches the target value
- the formed curd is crushed by stirring and cooled to 10 ° C. or lower to obtain a fermented product.
- the activity of lactic acid bacteria can be reduced and the production of acid can be suppressed.
- the fermented product obtained in the fermentation process is heat-treated to obtain a post-heated fermented product (fermented product after the heat treatment). By appropriately heating the fermented product, acid production by lactic acid bacteria in the fermented product after heating can be suppressed.
- Bifidobacterium breve M-16V (NITE BP-02622) is added to the post-heat fermentation product obtained in the heat treatment step.
- the amount of Bifidobacterium breve M-16V (NITE BP-02622) added is preferably 1 ⁇ 10 7 to 1 ⁇ 10 11 CFU / ml with respect to the fermented product after heating, and 1 ⁇ 10 8 to 1 ⁇ 10. 10 CFU / ml is more preferred.
- Bifidobacterium breve M-16V (NITE BP-02622) is dead, CFU / ml can be replaced with individual cells / ml.
- Bifidobacterium breve M-16V (NITE BP-02622) is added to the fermented product, followed by concentration.
- a concentration process can be performed using a well-known concentration method suitably. For example, a centrifugal separation method or a membrane separation method can be used. In the centrifugal separation method, whey in the product to be concentrated (fermented product after heating to which bifidobacteria are added) is removed, and concentrated fermented milk containing bifidobacteria with an increased solid content concentration is obtained.
- the fermented milk obtained as described above preference adjustment, body temperature maintenance, and blood vessel protection can be expected. Furthermore, it can be used for prevention or treatment of uneven eating, coldness, hypothermia, myocardial infarction, ischemia-reperfusion injury, cardiac hypertrophy, diabetic cardiomyopathy, arteriosclerosis, and vascular plaque formation.
- the resulting formula milk is dissolved in water, the total solids concentration of 14% with a standard milk formula Concentration (w / V) when the tone emulsions, tone number of bifidobacteria in the emulsion is 2.7 ⁇ 10 9 cfu / 100 ml.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Developmental Biology & Embryology (AREA)
- Pediatric Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Abstract
Description
FGF21の分泌が促進されることにより、全身レベルでの脂質利用能の亢進、エネルギー消費の亢進、肝臓におけるトリグリセリド蓄積の抑制や脂肪酸酸化の誘導などが起こることが報告されている(非特許文献2、3)。
また、対象がショ糖を摂取すると血清中のFGF21濃度が急激に上昇し、FGF21が対象のショ糖への嗜好性を減弱させることが報告されている(非特許文献4)。
また、新生児期では、血清中のFGF21濃度や肝臓のFGF21遺伝子発現の増加により体温が上昇するように、低体温症になりやすい新生児期においてFGF21は体温の維持に重要であることが報告されている(非特許文献5)。
また、FGF21は、例えば、心筋梗塞、虚血再灌流障害、心肥大、糖尿病性心筋症等にある対象の心機能の保護に重要であることが報告されている(非特許文献6)。
また、FGF21は、アテローム性動脈硬化において、血管内皮機能を改善することによりプラーク形成から血管を保護することが報告されている(非特許文献7、8)。
しかし、ビフィドバクテリウム属細菌を投与することにより体内でFGF21の分泌が促進されることは知られていない。
前記FGF21分泌促進用組成物は、嗜好性調節、体温維持又は血管保護のために用いられることを好ましい態様としている。
前記FGF21分泌促進用組成物は、偏食、冷え症、低体温症、心筋梗塞、虚血再灌流障害、心肥大、糖尿病性心筋症、動脈硬化又は血管プラーク形成の予防又は治療に用いられることを好ましい態様としている。
前記FGF21分泌促進用組成物は、プレバイオティクスを含むことを好ましい態様としている。
前記FGF21分泌促進用組成物は、前記プレバイオティクスが、ラクチュロース、ラフィノース及びガラクトオリゴ糖であることを好ましい態様としている。
前記FGF21分泌促進用組成物は、前記ビフィドバクテリウム属細菌がビフィドバクテリウム・ブレーベであることを好ましい態様としている。
前記FGF21分泌促進用組成物は、前記ビフィドバクテリウム・ブレーベが、ビフィドバクテリウム・ブレーベM-16V(NITE BP-02622)であることを好ましい態様としている。
前記FGF21分泌促進用組成物は、飲食品組成物であることを好ましい態様としている。
前記FGF21分泌促進用組成物は、医薬組成物であることを好ましい態様としている。
また、本発明の他の態様は、FGF21産生不全及び/又は分泌不全に起因する疾患、症候、症状又は障害の予防用組成物又は改善用組成物の製造における、ビフィドバクテリウム属細菌の使用である。
また、本発明の他の態様は、FGF21産生不全及び/又は分泌不全に起因する疾患、症候、症状又は障害の予防又は改善のために用いられる、ビフィドバクテリウム属細菌である。
また、本発明の他の態様は、FGF21産生不全及び/又は分泌不全に起因する疾患、症候、症状又は障害の予防又は改善のための、ビフィドバクテリウム属細菌の使用である。
また、本発明の他の態様は、ビフィドバクテリウム属細菌を、FGF産生不全及び/又は分泌不全に起因する疾患、症候、症状又は障害の予防又は改善が必要な対象に投与する段階を含む、FGF21産生不全及び/又は分泌不全に起因する疾患、症候、症状又は障害を予防又は改善する方法である。
本発明のFGF21分泌促進用組成物は、ビフィドバクテリウム属細菌を有効成分として含む。以下、同細菌を「本細菌」と記載することがある。
尚、本発明のFGF21分泌促進用組成物は、混合物を含む概念であり、FGF21分泌促進用組成物の成分が均一であるか不均一であるかを問わない。
本発明におけるFGF21分泌促進作用とは、哺乳動物が本細菌を摂取した(本明細書では、「投与された」場合を含む。)ときに、摂取しない(本明細書では、「投与しない」場合を含む。)ときよりも、FGF21の分泌量が大きいことを意味する。
このとき、FGF21の分泌量が大きいことは、FGF21遺伝子の発現がオフからオンになったことに起因してもよいし、FGF21遺伝子の発現が促進されたことに起因してもよいし、FGF21遺伝子がそもそも発現していたものの分泌がされていなかった状態が分泌される状態になったことに起因してもよい。該FGF21遺伝子は、好ましくは肝臓のFGF21遺伝子である。また、FGF21の分泌量が大きいことは、例えば、血清中のFGF21濃度を測定することで判断できる。
ビフィドバクテリウム属細菌は、その細菌を哺乳動物に摂取させたときにFGF21の分泌を促進し得るものであれば特に制限されない。例えば、ビフィドバクテリウム・ロンガム・サブスピーシーズ・ロンガム(Bifidobacterium longum subsp. longum)、ビフィドバクテリウム・ラクティス(Bifidobacterium lactis)、ビフィドバクテリウム・アニマリス(Bifidobacterium animalis)、ビフィドバクテリウム・ブレーベ(Bifidobcterium breve)、ビフィドバクテリウム・ロンガム・サブスピーシーズ・インファンティス(Bifidobacterium longum subsp. infantis)、ビフィドバクテリウム・アドレセンティス(Bifidobacterium adolescentis)等を使用することが出来る。尚、ビフィドバクテリウム・ロンガム・サブスピーシーズ・ロンガムは、単にビフィドバクテリウム・ロンガム(Bifidobacterium longum)と略される場合がある。また、ビフィドバクテリウム・ロンガム・サブスピーシーズ・インファンティスは、単にビフィドバクテリウム・インファンティス(Bifidobacterium infantis)と略される場合がある。
また、その中でも、ビフィドバクテリウム・ブレーベFERM BP-11175、ビフィドバクテリウム・ブレーベM-16V(NITE BP-02622)、ビフィドバクテリウム・ロンガム・サブスピーシーズ・ロンガムBB536(NITE BP-02621)、及びビフィドバクテリウム・ロンガム・サブスピーシーズ・インファンティスM-63(NITE BP-02623)がより好ましい。
NITE BP-02622の受託番号が付与された細菌は、2018年1月26日付で、独立行政法人製品評価技術基盤機構特許微生物寄託センター(〒292-0818 千葉県木更津市かずさ鎌足2-5-8 122号室)に、NITE BP-02622の受託番号で、ブダペスト条約に基づく国際寄託がなされたものである。
NITE BP-02621の受託番号が付与された細菌は、2018年1月26日付で、独立行政法人製品評価技術基盤機構特許微生物寄託センター(〒292-0818 千葉県木更津市かずさ鎌足2-5-8 122号室)に、NITE BP-02621の受託番号で、ブダペスト条約に基づく国際寄託がなされたものである。
NITE BP-02623の受託番号が付与された細菌は、2018年1月26日付で、独立行政法人製品評価技術基盤機構特許微生物寄託センター(〒292-0818 千葉県木更津市かずさ鎌足2-5-8 122号室)に、NITE BP-02623の受託番号で、ブダペスト条約に基づく国際寄託がなされたものである。
プレバイオティクスは、本細菌とともに哺乳動物に摂取させたときにFGF21の分泌を促進し得るものであれば特に制限されないが、例えば、ラクチュロース、ラフィノース、ガラクトオリゴ糖、フラクトオリゴ糖、大豆オリゴ糖、乳果オリゴ糖、キシロオリゴ糖、イソマルオリゴ糖、コーヒー豆マンノオリゴ糖、グルコン酸、ポリデキストロース、イヌリン等が好ましく、ラクチュロース、ラフィノース及びガラクトオリゴ糖がより好ましい。
該機能(活性)としては、例えば、嗜好性調節、体温維持、血管保護等を挙げることができる。したがって、本発明のFGF21分泌促進用組成物は、嗜好性調節、体温維持、血管保護等のために用いられることが好ましい。
尚、本発明のFGF21分泌促進用組成物の使用は、治療的使用であっても非治療的使用であってもよい。なお、「非治療的」とは、医療行為、すなわち治療による人体への処置行為を含まない概念である。
嗜好性の調節は、嗜好性の増強及び抑制を含む。嗜好性の増強とは、哺乳動物が本細菌を摂取したときに、摂取しないときよりも、食餌の嗜好性や味覚の嗜好性等が増強されることである。一方、嗜好性の抑制とは、哺乳動物が本細菌を摂取したときに、摂取しないときよりも、食餌の嗜好性や味覚の嗜好性等が抑制されることである。
嗜好性の調節により、例えば、哺乳動物の摂取する食餌の種類の偏りを減少させ、好き嫌いなく満遍なく広い種類の食餌が摂取できるようになり、また、味覚が調整される。本明細書における嗜好性の調節には、例えば、1)食餌の偏りによる好き嫌いが少なくなる、2)甘味偏重の嗜好性が抑制される、3)糖、人工甘味料の摂取が抑制される、4)苦味の強いもの、酸味の強いものが食べられるようになる、5)塩味の嗜好性が抑制され、低塩分の食事を好むようになる、6)アルコール嗜好性が抑制される等が含まれる。
前記飲食物としては特に制限されない。また、前記特定の成分としては、例えば、甘味成分が挙げられる。甘味成分は、糖質系甘味成分と非糖質系甘味成分とを含む。
糖類は、単糖類、二糖類、三糖以上の糖類であってよく、例えば、グルコース、マルトース、フルクトース、トレハロース、ラクトース、フラクトオリゴ糖、ガラクトオリゴ糖、キシロオリゴ糖、乳果オリゴ糖(登録商標)、大豆オリゴ糖、イソマルトオリゴ糖等が挙げられ、また、単糖類の混合物である水飴や異性化糖等であってもよい。
糖アルコールとしては、例えば、ソルビトール、マンニトール、マルチトール、キシリトール、エリスリトール、還元パラチノース等が挙げられ、また、単糖類の混合物である水飴を還元した還元水飴であってもよい。
非糖質系天然甘味成分としては、例えば、ステビア、グリチルリチン等が挙げられる。
非糖質系人工甘味成分としては、例えば、サッカリン、アスパルテーム、アセスルファムK、スクラロース等が挙げられる。
低体温状態に向かう状態を体温上昇により防ぐ体温維持とは、具体的には、哺乳動物が本細菌を摂取しない場合には低体温状態に向かう状態において、本細菌を摂取することにより体温低下を防ぎ、低体温状態になることを防ぐことを意味する。低体温状態とは、脇の下の体温が、好ましくは36.5℃以下、より好ましくは36.0℃以下、さらに好ましくは35.5℃以下、よりさらに好ましくは35.0℃以下の状態、又は、深部体温が35.0℃以下の状態を言うものとする。
また、前述の通り、本発明におけるFGF21分泌促進作用は、FGF21遺伝子の発現がオフからオンになったことに起因してもよいし、FGF21遺伝子の発現が促進されたことに起因してもよいし、FGF21遺伝子がそもそも発現していたものの分泌がされていなかった状態が分泌される状態になったことに起因してもよいことから、前記FGF21の分泌促進によって予防又は治療され得る疾患、症候、症状又は障害等には、FGF21産生不全及び/又はFGF21分泌不全に起因する疾患、症候、症状又は障害等も含まれる。分泌不全には分泌低下も含まれる。
このような疾患、症候、症状又は障害としては、例えば、偏食、冷え症、低体温症、心筋梗塞、虚血再灌流障害、心肥大、糖尿病性心筋症、動脈硬化、血管プラーク形成等が挙げられる。
また、飲食品組成物は、サプリメントであってもよく、例えばタブレット状のサプリメントであってもよい。サプリメントである場合には、一日当りの食事量及び摂取カロリーについて他の食品に影響されることなく、本細菌を摂取できる。
飲食品組成物の原料としては、通常の飲食品に用いられる原料を使用することができる。製造された飲食品組成物は、経口的に摂取することが可能である。
また、プレバイオティクスがラクチュロース、ラフィノース、及びガラクトオリゴ糖である場合、それらの重量比は、1~9:1~9:1~9、好ましくは2~8:2~8:2~8、より好ましくは3~7:3~7:3~7であることが好ましい。
具体的には、本発明のFGF21分泌促進用飲食品組成物又はFGF21分泌促進用飲食品に係る商品又は商品の包装に上記用途を記載する行為、商品又は商品の包装に上記用途を記載したものを譲渡し、引渡し、譲渡若しくは引渡しのために展示し、輸入する行為、商品に関する広告、価格表若しくは取引書類に上記用途を記載して展示し、若しくは頒布し、又はこれらを内容とする情報に上記用途を記載して電磁気的(インターネット等)方法により提供する行為等が例示でき、特に包装、容器、カタログ、パンフレット、POP等の販売現場における宣伝材、その他の書類等への表示が好ましい。
なお、経口投与用の液剤の場合に使用する担体としては、水等の溶剤、矯味矯臭剤等が挙げられる。
また、本発明の他の態様は、FGF21分泌促進に用いられるビフィドバクテリウム属細菌である。
また、本発明の他の態様は、FGF21分泌促進のための、ビフィドバクテリウム属細菌の使用である。
また、本発明の他の態様は、ビフィドバクテリウム属細菌を哺乳動物に投与する段階又は本発明のFGF21分泌促進用組成物を哺乳動物に投与する段階を含む、FGF21分泌を促進する方法である。
また、本発明の他の態様は、嗜好性調節、体温維持又は血管保護に用いられるビビフィドバクテリウム属細菌である。
また、本発明の他の態様は、嗜好性調節、体温維持又は血管保護のための、ビフィドバクテリウム属細菌の使用である。
また、本発明の他の態様は、ビフィドバクテリウム属細菌を哺乳動物に投与する段階又は本発明のFGF21分泌促進用組成物を哺乳動物に投与する段階を含む、FGF21の分泌促進による、嗜好性調節方法、体温維持方法、血管保護方法である。
また、本発明の他の態様は、偏食、冷え症、低体温症、心筋梗塞、虚血再灌流障害、心肥大、糖尿病性心筋症、動脈硬化又は血管プラーク形成の予防又は治療に用いられる、ビフィドバクテリウム属細菌である。
また、本発明の他の態様は、偏食、冷え症、低体温症、心筋梗塞、虚血再灌流障害、心肥大、糖尿病性心筋症、動脈硬化又は血管プラーク形成の予防又は治療のための、ビフィドバクテリウム属細菌の使用である。
また、本発明の他の態様は、ビフィドバクテリウム属細菌を哺乳動物に投与する段階又は本発明のFGF21分泌促進用組成物を哺乳動物に投与する段階を含む、偏食、冷え症、低体温症、心筋梗塞、虚血再灌流障害、心肥大、糖尿病性心筋症、動脈硬化又は血管プラーク形成の予防方法又は治療方法である。
でん粉に倍散したビフィドバクテリウム・ブレーベM-16V (NITE BP-02622)の菌体粉末(2.4×1011cfu/g)を生理食塩水に懸濁し、2.5×109cfu/mlのビフィズス菌液を調製した。
ラクチュロース(森永乳業社製)、ラフィノース(製品名ニッテンラフィノース、日本甜菜製糖株式会社製)、及びガラクトオリゴ糖を蒸留水に1:1:1の重量比で混合溶解し、合計終濃度250mg/mlのオリゴ糖原液を調製した。ガラクトオリゴ糖は、市販品(製品名オリゴメイト55N、ヤクルト薬品工業社製)から単糖及び二糖を除去したものであり、Galβ1-4Galβ1-4Glc(4'-ガラクトシルラクトース)を約65重量%、Galβ1-6Galβ1-4Glc(6'-ガラクトシルラクトース)を約15重量%程度含有する。
生理食塩水、上記ビフィズス菌液を生理食塩水で5倍希釈した希釈液(終濃度5×108cfu/mlビフィズス菌)、生理食塩水とオリゴ糖原液を1:4の容量比で混合したもの(終濃度200mg/mlオリゴ糖)、及び、ビフィズス菌液とオリゴ糖原液を1:4の容量比で混合したもの(終濃度5×108cfu/mlビフィズス菌、200mg/mlオリゴ糖)を、投与物とした。
A:Vehicle群(生理食塩水を投与)
B:ビフィズス菌群(ビフィズス菌液希釈液を投与)
C:オリゴ糖群(オリゴ糖液を投与)
D:オリゴ糖+ビフィズス菌群(オリゴ糖とビフィズス菌の混合液を投与)
21日齢で各々解剖を行い、血清、及び肝臓を採取し、血清中のFGF21濃度、及び肝臓のFGF21遺伝子の発現量を調べた。血清中のFGF21濃度は、ELISAキット(R&D Systems社製)を用いて測定した。肝臓のFGF21遺伝子の発現量はRT-PCRにより測定した。RT-PCRにおけるプライマーセットとして、配列番号1のプライマー(CCTCTAGGTTTCTTTGCCAACAG)及び配列番号2のプライマー(AAGCTGCAGGCCTCAGGAT)を用いた。結果を表1、2に示す。
また、表2に示されるように、A群、B群及びC群に比べてD群では、血清中のFGF21濃度が顕著に大きかった。
ビフィドバクテリウム・ブレーベM-16V (NITE BP-02622)を、MRS液体培地3 mLに添加し、37℃で16時間嫌気培養後、培養液を濃縮し、凍結乾燥を行い、細菌の凍結乾燥粉末(菌末)を得る。菌末と、ホエイタンパク質濃縮物(Whey protein concentrate; WPC)とを均一に混合して組成物を得る。当該組成物20 gを200 gの水に溶かし、FGF21分泌促進用組成物を得る。本組成物の投与により、嗜好性調節、体温維持、血管保護が期待できる。さらに、偏食、冷え症、低体温症、心筋梗塞、虚血再灌流障害、心肥大、糖尿病性心筋症、動脈硬化、血管プラーク形成の予防又は治療に用いることが出来る。
ビフィドバクテリウム・ブレーベM-16V (NITE BP-02622)を、MRS液体培地3 mLに添加し、37℃で16時間嫌気培養後、培養液を濃縮し、凍結乾燥を行い、細菌の凍結乾燥粉末(菌末)を得る。菌末と、乳タンパク質濃縮物の乾燥粉末(MPC480、フォンテラ社製、タンパク質含量80質量%、カゼインタンパク質:ホエイタンパク質=約8:2)とを均一に混合して、組成物を得る。当該組成物20 gを200 gの水に溶かし、FGF21分泌促進用組成物を得る。本組成物の投与により、嗜好性調節、体温維持、血管保護が期待できる。さらに、偏食、冷え症、低体温症、心筋梗塞、虚血再灌流障害、心肥大、糖尿病性心筋症、動脈硬化、血管プラーク形成の予防又は治療に用いることが出来る。
ビフィドバクテリウム・ブレーベM-16V (NITE BP-02622)を、MRS液体培地3 mLに添加し、37℃で16時間嫌気培養後、培養液を濃縮し、凍結乾燥を行い、細菌の凍結乾燥粉末(菌末)を得る。次に、結晶セルロースを撹拌造粒機に投入し混合する。その後、精製水を加え造粒、造粒物を乾燥し、細菌の抽出成分を含有し、賦形剤を含有してなる造粒物を得る。本組成物の投与により、嗜好性調節、体温維持、血管保護が期待できる。さらに、偏食、冷え症、低体温症、心筋梗塞、虚血再灌流障害、心肥大、糖尿病性心筋症、動脈硬化、血管プラーク形成の予防又は治療に用いることが出来る。
ビフィドバクテリウム・ブレーベM-16V (NITE BP-02622)をMRS液体培地3 mLに添加し、37℃で16時間嫌気培養し、培養液を濃縮し、凍結乾燥を行い、該細菌の凍結乾燥粉末(菌末)を得る。菌末と、プレバイオティクス(ラクチュロース、ラフィノース及びガラクトオリゴ糖)とを均一に混合して組成物を得る。当該組成物を、高齢者用流動食として高齢者に提供する。ビフィドバクテリウム・ブレーベM-16V (NITE BP-02622)の摂取量が1×108~1×1010CFU/kg体重/日になるようにし、1週間毎日朝食で提供する。ビフィドバクテリウム・ブレーベM-16V (NITE BP-02622)が死菌の場合、CFU/kg体重/日は、個細胞/kg体重/日と置き換えることができる。なお、発酵乳等の飲食物と混合してもよい。当該組成物を経口投与することにより、嗜好性調節、体温維持、血管保護が期待できる。さらに、偏食、冷え症、低体温症、心筋梗塞、虚血再灌流障害、心肥大、糖尿病性心筋症、動脈硬化、血管プラーク形成の予防又は治療に用いることが出来る。
ビフィドバクテリウム・ブレーベM-16V (NITE BP-02622)を添加した発酵乳の製造法を下記に示す。
まず、乳原料、および必要に応じた水、その他の成分等を混合し、好ましくは均質化処理を行い、加熱殺菌処理する。均質化処理および加熱殺菌処理は常法により行うことができる。加熱殺菌された 殺菌調乳液に乳酸菌スターターを添加(接種)し、所定の発酵温度に保持して発酵させ、発酵物を得る。発酵によりカードが形成される。
乳酸菌スターターとしては、例えば、ラクトバチルス・ブルガリクス(Lactobacillus bulgaricus)、ラクトコッカス・ラクチス(Lactococcus lactis)、ストレプトコッカス・サーモフィラス(Streptococcus thermophilus)等のヨーグルト製造に通常用いられている乳酸菌を用いることができる。pHが目標の値に達したら、形成されたカードを撹拌により破砕し、10℃以下に冷却して発酵物を得る。10℃以下に冷却することにより、乳酸菌の活性を低下させて酸の生成を抑制することができる。
次いで、発酵工程で得られた発酵物を加熱処理して加熱後発酵物(加熱処理後の発酵物)を得る。発酵物を適度に加熱することにより、加熱後発酵物中の乳酸菌による酸の生成を抑えることができる。これによって、その後の製造工程中および/またはビフィズス菌入り濃縮発酵乳の保存中のpHの低下を抑えることができ、その結果、ビフィズス菌の生残性を向上させることができる。
次いで、加熱処理工程で得られた加熱後発酵物に、ビフィドバクテリウム・ブレーベM-16V (NITE BP-02622)を添加する。ビフィドバクテリウム・ブレーベM-16V (NITE BP-02622)の添加量は、加熱後発酵物に対して1×107~1×1011CFU/mlが好ましく、1×108~1×1010CFU/mlがより好ましい。ビフィドバクテリウム・ブレーベM-16V (NITE BP-02622)が死菌の場合、CFU/mlは、個細胞/mlと置き換えることができる。
加熱後発酵物にビフィドバクテリウム・ブレーベM-16V (NITE BP-02622)を添加した後、濃縮を行う。濃縮工程は公知の濃縮方法を適宜用いて行うことができる。例えば遠心分離法または膜分離法を用いることができる。
遠心分離法では、被濃縮物(ビフィズス菌が添加された加熱後発酵物)中のホエーが除去されて、固形分濃度が高められたビフィズス菌入り濃縮発酵乳が得られる。
上述のようにして得られた発酵乳を摂取することにより、嗜好性調節、体温維持、血管保護が期待できる。さらに、偏食、冷え症、低体温症、心筋梗塞、虚血再灌流障害、心肥大、糖尿病性心筋症、動脈硬化、血管プラーク形成の予防又は治療に用いることが出来る。
ビフィドバクテリウム・ブレーベM-16V (NITE BP-02622)を添加した調製粉乳の製造法を下記に示す。
脱塩牛乳乳清蛋白質粉末(ミライ社製)10kg、牛乳カゼイン粉末(フォンテラ社製)6kg、乳糖(ミライ社製)48kg、ミネラル混合物(富田製薬社製)920g、ビタミン混合物(田辺製薬社製)32g、ラクチュロース(森永乳業社製)500g、ラフィノース(日本甜菜製糖社製)500g、及びガラクトオリゴ糖液糖(ヤクルト薬品工業社製)900gを温水300kgに溶解し、さらに90℃で10分間加熱溶解し、調製脂肪(太陽油脂社製)28kgを添加して均質化する。その後、殺菌、濃縮の工程を行って噴霧乾燥し、調製粉乳約95kgを調製する。これに、でん粉に倍散したビフィドバクテリウム・ブレーベM-16V (NITE BP-02622)の菌体粉末(1.8×1011cfu/g、森永乳業社製)100gを加えてビフィズス菌・オリゴ糖配合調製粉乳約95kgを調製する。得られた調製粉乳を水に溶解して、標準調乳濃度である総固形分濃度14%(w/V)の調乳液としたとき、調乳液中のビフィズス菌数は2.7×109cfu/100mlとなる。上述のようにして得られた調整粉乳を摂取することにより、嗜好性調節、体温維持、血管保護が期待できる。さらに、偏食、冷え症、低体温症、心筋梗塞、虚血再灌流障害、心肥大、糖尿病性心筋症、動脈硬化、血管プラーク形成の予防又は治療に用いることが出来る。
Claims (13)
- ビフィドバクテリウム属細菌を有効成分とする、FGF21分泌促進用組成物。
- 嗜好性調節、体温維持又は血管保護のために用いられる、請求項1に記載の組成物。
- 偏食、冷え症、低体温症、心筋梗塞、虚血再灌流障害、心肥大、糖尿病性心筋症、動脈硬化又は血管プラーク形成の予防又は治療に用いられる、請求項1に記載の組成物。
- プレバイオティクスを含む、請求項1~3のいずれか1項に記載の組成物。
- 前記プレバイオティクスが、ラクチュロース、ラフィノース及びガラクトオリゴ糖である、請求項4に記載の組成物。
- 前記ビフィドバクテリウム属細菌がビフィドバクテリウム・ブレーベである、請求項1~5のいずれか1項に記載の組成物。
- 前記ビフィドバクテリウム・ブレーベが、ビフィドバクテリウム・ブレーベM-16V(NITE BP-02622)である、請求項6に記載の組成物。
- 飲食品組成物である、請求項1~7のいずれか1項に記載の組成物。
- 医薬組成物である、請求項1~7のいずれか1項に記載の組成物。
- FGF21産生不全及び/又は分泌不全に起因する疾患、症候、症状又は障害の予防用組成物又は改善用組成物の製造における、ビフィドバクテリウム属細菌の使用。
- FGF21産生不全及び/又は分泌不全に起因する疾患、症候、症状又は障害の予防又は改善のために用いられる、ビフィドバクテリウム属細菌。
- FGF21産生不全及び/又は分泌不全に起因する疾患、症候、症状又は障害の予防又は改善のための、ビフィドバクテリウム属細菌の使用。
- ビフィドバクテリウム属細菌を、FGF産生不全及び/又は分泌不全に起因する疾患、症候、症状又は障害の予防又は改善が必要な対象に投与する段階を含む、FGF21産生不全及び/又は分泌不全に起因する疾患、症候、症状又は障害を予防又は改善する方法。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18910930.9A EP3769771A4 (en) | 2018-03-23 | 2018-03-23 | COMPOSITION PROMOTING SECRETION OF FGF21 |
US16/980,692 US11857579B2 (en) | 2018-03-23 | 2018-03-23 | Composition for promoting the secretion of FGF21 |
AU2018414925A AU2018414925B2 (en) | 2018-03-23 | 2018-03-23 | Composition for promoting the secretion of FGF21 |
JP2020507284A JP7152472B2 (ja) | 2018-03-23 | 2018-03-23 | Fgf21分泌促進用組成物 |
CN201880091708.9A CN111936155B (zh) | 2018-03-23 | 2018-03-23 | 促进fgf21分泌用组合物 |
PCT/JP2018/011917 WO2019180964A1 (ja) | 2018-03-23 | 2018-03-23 | Fgf21分泌促進用組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2018/011917 WO2019180964A1 (ja) | 2018-03-23 | 2018-03-23 | Fgf21分泌促進用組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019180964A1 true WO2019180964A1 (ja) | 2019-09-26 |
Family
ID=67988322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/011917 WO2019180964A1 (ja) | 2018-03-23 | 2018-03-23 | Fgf21分泌促進用組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11857579B2 (ja) |
EP (1) | EP3769771A4 (ja) |
JP (1) | JP7152472B2 (ja) |
CN (1) | CN111936155B (ja) |
AU (1) | AU2018414925B2 (ja) |
WO (1) | WO2019180964A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021104951A (ja) * | 2019-12-26 | 2021-07-26 | 小林製薬株式会社 | Fgf21産生促進剤 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03169888A (ja) | 1989-11-28 | 1991-07-23 | Morinaga Milk Ind Co Ltd | 精製ラクチュロースの製造法 |
JPH06228179A (ja) | 1993-02-02 | 1994-08-16 | Morinaga Milk Ind Co Ltd | ラクチュロース無水物の製造法 |
JPH10130160A (ja) * | 1996-10-29 | 1998-05-19 | Yakult Honsha Co Ltd | 脂質代謝改善剤及びそれを含有する食品 |
JPH10175867A (ja) * | 1996-12-12 | 1998-06-30 | Morinaga Milk Ind Co Ltd | ビフィズス菌増殖促進組成物及びその用途 |
WO2008120712A1 (ja) | 2007-03-30 | 2008-10-09 | Suntory Holdings Limited | 交感神経活動亢進作用を有する医薬組成物又は飲食物 |
WO2010071421A1 (en) * | 2008-12-17 | 2010-06-24 | N.V. Nutricia | Probiotics for the treatment and/or prevention of pulmonary hypertension |
JP2013505283A (ja) * | 2009-09-23 | 2013-02-14 | プロベルテ ファーマ,エス.エー. | プレバイオティックスとしての植物抽出物の使用、当該植物抽出物を含有する組成物及び食品 |
WO2017009187A1 (en) * | 2015-07-16 | 2017-01-19 | Dupont Nutrition Biosciences Aps | Bifidobacteria for treating cardiac conditions |
WO2017145415A1 (ja) * | 2016-02-26 | 2017-08-31 | 森永乳業株式会社 | 免疫発達促進剤 |
JP2017203030A (ja) * | 2016-05-10 | 2017-11-16 | 協同乳業株式会社 | 動脈硬化症を予防するためのプロバイオティクス組成物および方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100396771C (zh) | 2004-05-10 | 2008-06-25 | 景岳生物科技股份有限公司 | 新的微生物株类干酪乳杆菌gm-080及其治疗过敏相关疾病的用途 |
TW200719833A (en) | 2005-03-24 | 2007-06-01 | Suntory Ltd | Novel microorganism and method of processing fresh coffee beans by using the same |
BRPI0615785B8 (pt) * | 2005-09-08 | 2021-05-25 | Yakult Honsha Kk | composição inibidora da absorção de colesterol compreendendo bactérias do gênero bifidobacterium |
EP1974734A1 (en) * | 2007-03-28 | 2008-10-01 | Nestec S.A. | Probiotics for reduction of risk of obesity |
WO2008153377A1 (en) * | 2007-06-15 | 2008-12-18 | N.V. Nutricia | Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide |
US8497114B2 (en) * | 2009-09-17 | 2013-07-30 | Morinaga Milk Industry Co., Ltd. | Anti-obesity agent, anti-obesity food or beverage, glucose tolerance-ameliorating agent, and food or beverage for amelioration of glucose tolerance |
-
2018
- 2018-03-23 JP JP2020507284A patent/JP7152472B2/ja active Active
- 2018-03-23 WO PCT/JP2018/011917 patent/WO2019180964A1/ja unknown
- 2018-03-23 CN CN201880091708.9A patent/CN111936155B/zh active Active
- 2018-03-23 US US16/980,692 patent/US11857579B2/en active Active
- 2018-03-23 AU AU2018414925A patent/AU2018414925B2/en active Active
- 2018-03-23 EP EP18910930.9A patent/EP3769771A4/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03169888A (ja) | 1989-11-28 | 1991-07-23 | Morinaga Milk Ind Co Ltd | 精製ラクチュロースの製造法 |
JPH06228179A (ja) | 1993-02-02 | 1994-08-16 | Morinaga Milk Ind Co Ltd | ラクチュロース無水物の製造法 |
JPH10130160A (ja) * | 1996-10-29 | 1998-05-19 | Yakult Honsha Co Ltd | 脂質代謝改善剤及びそれを含有する食品 |
JPH10175867A (ja) * | 1996-12-12 | 1998-06-30 | Morinaga Milk Ind Co Ltd | ビフィズス菌増殖促進組成物及びその用途 |
WO2008120712A1 (ja) | 2007-03-30 | 2008-10-09 | Suntory Holdings Limited | 交感神経活動亢進作用を有する医薬組成物又は飲食物 |
WO2010071421A1 (en) * | 2008-12-17 | 2010-06-24 | N.V. Nutricia | Probiotics for the treatment and/or prevention of pulmonary hypertension |
JP2013505283A (ja) * | 2009-09-23 | 2013-02-14 | プロベルテ ファーマ,エス.エー. | プレバイオティックスとしての植物抽出物の使用、当該植物抽出物を含有する組成物及び食品 |
WO2017009187A1 (en) * | 2015-07-16 | 2017-01-19 | Dupont Nutrition Biosciences Aps | Bifidobacteria for treating cardiac conditions |
WO2017145415A1 (ja) * | 2016-02-26 | 2017-08-31 | 森永乳業株式会社 | 免疫発達促進剤 |
JP2017203030A (ja) * | 2016-05-10 | 2017-11-16 | 協同乳業株式会社 | 動脈硬化症を予防するためのプロバイオティクス組成物および方法 |
Non-Patent Citations (12)
Title |
---|
DOMOUZOGLOU EM., AM. J. PHYSIOL. HEART CIRC. PHYSIOL., vol. 309, no. 6, 2015, pages H1029 - 38 |
HONDARES E. ET AL., CELL METAB., vol. 11, no. 3, 2010, pages 206 - 12 |
ITOH ET AL., TRENDS GENET., vol. 20, no. 11, 2004, pages 563 - 69 |
KAZUTOSHI CHAYAMA; DAIGO MORI; UYUNSTIN; TAKAO; SHIZUKI KONDO; TAKUMI SATO; KINCHU SHIMIZU: "Bifidobacterium suppresses the onset of mouse arteriosclerosis", JAPANESE JOURNAL OF LACTIC ACID BACTERIA, vol. 22, no. 2, 1 January 2011 (2011-01-01), pages 1 - 3, XP009523950, ISSN: 1343-327X * |
KHARITONENKOV, A. ET AL., ENDOCRINOLOGY, vol. 148, 2007, pages 774 - 781 |
LAU K. ET AL.: "Bridging the gap between gut microbial dysbiosis and cardiovascular diseases", NUTRIENTS, vol. 9, no. 8, 2017, pages 1 - 17, XP055636154, ISSN: 2072-6643 * |
LIN Z., CIRCULATION, vol. 131, no. 21, 2015, pages 1861 - 71 |
LIU HX. ET AL.: "Microbiota and bile acid profiles in retinoic acid-primed mice that exhibit accelerated liver regeneration", ONCOTARGET, vol. 7, no. 2, 2015, pages 1096 - 1106, XP055636157, ISSN: 1949-2553 * |
PONGPAN TANAJAK ET AL., J. ENDOCRINOL., vol. 227, 2015, pages R13 - R30 |
RYDEN, M. ET AL., CELL. MOL. LIFE SCI., vol. 66, 2009, pages 2067 - 2073 |
SOBERG S. ET AL., CELL METAB., vol. 25, no. 5, 2017, pages 1045 - 1053 |
WANG H. ET AL.: "Bifidobacteria may be benefical to intestinal microbiota and reduction of bacterial translocation in mice following ishaemia and reperfusion injury", BR J NUTRI., vol. 109, 2013, pages 1990 - 1998, XP055636161, ISSN: 0007-1145 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021104951A (ja) * | 2019-12-26 | 2021-07-26 | 小林製薬株式会社 | Fgf21産生促進剤 |
JP7475597B2 (ja) | 2019-12-26 | 2024-04-30 | 小林製薬株式会社 | Fgf21産生促進剤 |
Also Published As
Publication number | Publication date |
---|---|
US11857579B2 (en) | 2024-01-02 |
AU2018414925B2 (en) | 2023-05-04 |
CN111936155B (zh) | 2023-08-18 |
EP3769771A1 (en) | 2021-01-27 |
AU2018414925A1 (en) | 2020-11-12 |
JPWO2019180964A1 (ja) | 2020-12-03 |
EP3769771A4 (en) | 2021-11-03 |
US20210008129A1 (en) | 2021-01-14 |
JP7152472B2 (ja) | 2022-10-12 |
CN111936155A (zh) | 2020-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPWO2019117212A1 (ja) | ビフィドバクテリウム属細菌を有効成分とする組成物 | |
CN111935995A (zh) | 营养组合物以及使用了该营养组合物的饮食品组合物和配方奶粉 | |
WO2020246585A1 (ja) | 栄養組成物 | |
US11825856B2 (en) | Composition for preventing or improving functional gastrointestinal disorders, and, pharmaceutical composition, food/beverage composition, and method of preventing or improving functional gastrointestinal disorders using the composition for preventing or improving functional gastrointestinal disorders | |
US11324784B2 (en) | Sleep-promoting composition, and medical composition and food beverage composition using said sleep-promoting composition | |
WO2021149663A1 (ja) | 組成物 | |
JP2019116423A (ja) | 整腸用組成物 | |
WO2019188943A1 (ja) | 脳血流低下の予防及び/又は改善用組成物 | |
JP7152472B2 (ja) | Fgf21分泌促進用組成物 | |
JP7368484B2 (ja) | 組成物並びに該組成物含有する飲食品組成物および調製乳 | |
JP6847577B2 (ja) | ビフィドバクテリウム属細菌および/または乳酸菌の増殖促進および/または減少抑制剤 | |
JP7522043B2 (ja) | ノロウイルス感染抑制用組成物 | |
WO2021025154A1 (ja) | 学童期の記憶能向上のための乳幼児用組成物 | |
JP7266580B2 (ja) | 学童期以降の高血糖に起因する疾患の予防のための乳幼児用組成物 | |
WO2020251044A1 (ja) | ビフィドバクテリウム属細菌を有効成分とする組成物 | |
JP7333732B2 (ja) | 筋肉量及び/又は筋力の維持、或いは筋肉量及び/又は筋力の低下抑制用組成物、並びに、該組成物を用いた医薬品組成物及び飲食品組成物 | |
JP7299744B2 (ja) | 血中尿酸値低減用組成物、及び高尿酸血症予防又は改善用組成物、並びに、該組成物を用いた医薬品組成物及び飲食品組成物 | |
JP2021042143A (ja) | 脂質代謝異常及び/又は糖代謝異常の予防又は改善用組成物、並びに、該組成物を用いた医薬品組成物及び飲食品組成物 | |
JP2023126304A (ja) | 腎機能障害予防又は改善用組成物、並びに、該腎機能障害予防又は改善用組成物を用いた医薬品組成物及び飲食品組成物 | |
JP2021042141A (ja) | 腎機能障害の予防又は改善用組成物、並びに、該組成物を用いた医薬品組成物及び飲食品組成物 | |
US20200338141A1 (en) | Composition for Reducing Blood Uric Acid Level and Composition for Preventing or Improving Hyperuricemia, Pharmaceutical Composition, Food/Beverage Composition, Method for Reducing Blood Uric Acid Level, and Method of Preventing or Improving Hyperuricemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18910930 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020507284 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018910930 Country of ref document: EP Effective date: 20201023 |
|
ENP | Entry into the national phase |
Ref document number: 2018414925 Country of ref document: AU Date of ref document: 20180323 Kind code of ref document: A |